Download PDF
Semin Thromb Hemost 2017; 43(03): 270-276
DOI: 10.1055/s-0036-1597297
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors

Elizabeth M. Van Cott
1   Department of Pathology GRJ235, Massachusetts General Hospital, Boston, Massachusetts
,
A. Joshua Roberts
2   Department of Pharmacy, University of California Davis Medical Center, Sacramento, California
,
William E. Dager
2   Department of Pharmacy, University of California Davis Medical Center, Sacramento, California
› Author Affiliations
Further Information

Publication History

Publication Date:
04 January 2017 (online)

    Permissions and Reprints

Abstract

Argatroban and bivalirudin are parenteral direct inhibitors of the activity of thrombin, but, unlike heparin, can inhibit both soluble as well as clot-bound thrombin. These agents do not require antithrombin as a cofactor for activity. The parenteral direct thrombin inhibitors (DTIs) can be used in a variety of settings, including heparin-induced thrombocytopenia (HIT) or an allergy to heparin, and patients requiring anticoagulation for an invasive cardiovascular intervention. Both agents have a relatively short half-life in patients without organ system failure and are typically administered by continuous infusion. Argatroban is primarily eliminated by the liver, while bivalirudin is removed by a combination of proteolytic cleavage by thrombin and renal clearance mechanisms. Several laboratory tests are available for monitoring the anticoagulant effects of the DTIs: the activated partial thromboplastin time (aPTT) and the activated clotting time (ACT) are the most commonly used assays, but on occasion, the thrombin time may be useful. Other coagulation assays such as the dilute thrombin time (dTT), chromogenic anti-IIa assays, and the ecarin clotting time (ECT) can be used. The intensity of anticoagulation with DTIs depends on the indication for use. For patients with HIT, the target aPTT is 1.5 to 3.0 and 1.5 to 2.5 times the patient's baseline value for argatroban and bivalirudin, respectively. DTI anticoagulation used during percutaneous coronary intervention can be measured using ACT. Both DTIs may cause an elevation in the international normalized ratio depending on their plasma concentration. This article will review the use of parenteral DTIs and related laboratory assays for assessing the anticoagulant effect of these drugs.

Keywords

argatroban - bivalirudin - laboratory monitoring
 

  • References

  • 1 Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ. for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl): 7S-47S
    CrossrefPubMedGoogle Scholar
  • 2 https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Argatroban/pdf/ARGATROBAN.PDF . Accessed October 13, 2015
    PubMed
  • 3 Angiomax. Package Insert. The Medicines Company Parsippany. NJ 07054. 2013
    PubMedGoogle Scholar
  • 4 Linkins LA, Dans AL, Moores LK , et al; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e495S-e530S
    CrossrefPubMedGoogle Scholar
  • 5 Anticoagulation Guideline ELSO. The Extracorporeal Life Support Organization (ELSO), Ann Arbor, MI, USA. 2014 . ELSO.org. Accessed December 25, 2015
    PubMedGoogle Scholar
  • 6 Dyke CM, Smedira NG, Koster A , et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131 (3) 533-539
    CrossrefPubMedGoogle Scholar
  • 7 Smedira NG, Dyke CM, Koster A , et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131 (3) 686-692
    CrossrefPubMedGoogle Scholar
  • 8 Koster A, Dyke CM, Aldea G , et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83 (2) 572-577
    CrossrefPubMedGoogle Scholar
  • 9 Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 2007; 27 (4) 564-587
    CrossrefPubMedGoogle Scholar
  • 10 Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002; 105 (5) 401-405
    CrossrefPubMedGoogle Scholar
  • 11 Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004; 38 (1) 25-29
    CrossrefPubMedGoogle Scholar
  • 12 Fox I, Dawson A, Loynds P , et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69 (2) 157-163
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e24S-e43S
    CrossrefPubMedGoogle Scholar
  • 14 Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 2005; 6 (8) 1349-1371
    CrossrefPubMedGoogle Scholar
  • 15 Dager WE, Tsu LV, Pon TK. Considerations for systemic anticoagulation in ESRD. Semin Dial 2015; 28 (4) 354-362
    CrossrefPubMedGoogle Scholar
  • 16 Tsu LV, Dager WE. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother 2011; 45 (10) 1185-1192
    CrossrefPubMedGoogle Scholar
  • 17 Runyan CL, Cabral KP, Riker RR , et al. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia. Pharmacotherapy 2011; 31 (9) 850-856
    CrossrefPubMedGoogle Scholar
  • 18 Gosselin RC, Dager WE, King JH , et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004; 121 (4) 593-599
    CrossrefPubMedGoogle Scholar
  • 19 Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007; 98 (1) 234-242
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Shaikh S, Van Cott EM. The effect of argatroban on activated protein C resistance. Am J Clin Pathol 2009; 131 (6) 828-833
    CrossrefPubMedGoogle Scholar
  • 21 Kim YA, Gosselin R, Van Cott EM. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol 2015; 37 (4) e81-e84
    CrossrefPubMedGoogle Scholar
  • 22 Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013; 139 (1) 102-109
    CrossrefPubMedGoogle Scholar
  • 23 Walenga JM, Fasanella AR, Iqbal O , et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999; 25 (Suppl. 01) 61-66
    PubMedGoogle Scholar
  • 24 Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127 (3) 177-185
    CrossrefPubMedGoogle Scholar
  • 25 Gosselin RC. Heparin induced thrombocytopenia in a post-operative cardiopulmonary bypass patient requiring extracorporeal and intra-aortic balloon support: diagnosis and management. American Society for Clinical Pathology, Check Sample April 2007.
    PubMedGoogle Scholar
  • 26 Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122 (9) 799-807
    PubMedGoogle Scholar
  • 27 Dager W. Parenteral Direct Thrombin Inhibitors. . In: Dager W, Gulseth M, Nutescu E, , eds. Anticoagulation Therapy: A Point-of-Care Guide. Bethesda, MD: American Society of Health-System Pharmacists; 2011
    Google Scholar
  • 28 Arpino PA, Goeller AJ, Fatalo A, Van Cott EM. Evaluation of 2 nomogram-based strategies for dosing argatroban in patients with known or suspected heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2015; 21 (3) 260-265
    CrossrefPubMedGoogle Scholar
  • 29 Kiser TH, Mann AM, Trujillo TC, Hassell KL. Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia. Am J Hematol 2011; 86 (3) 267-272
    CrossrefPubMedGoogle Scholar
  • 30 Gilmore JF, Adams CD, Blum RM, Fanikos J, Anne Hirning B, Matta L. Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia. Am J Hematol 2015; 90 (8) E143-E145
    CrossrefPubMedGoogle Scholar
  • 31 Lincoff AM, Bittl JA, Harrington RA , et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289 (7) 853-863
    CrossrefPubMedGoogle Scholar
  • 32 Shahzad A, Kemp I, Mars C , et al; HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; 384 (9957): 1849-1858
    CrossrefPubMedGoogle Scholar
  • 33 Stone GW, Witzenbichler B, Guagliumi G , et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21) 2218-2230
    CrossrefPubMedGoogle Scholar
  • 34 Roffi M, Patrono C, Collet JP , et al; 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (3) 267-315
    CrossrefPubMedGoogle Scholar
  • 35 Kastrati A, Neumann FJ, Mehilli J , et al; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359 (7) 688-696
    CrossrefPubMedGoogle Scholar
  • 36 Chia S, Van Cott EM, Raffel OC, Jang IK. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemost 2009; 101 (3) 535-540
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85 (3) 185-187
    PubMedGoogle Scholar
  • 38 Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 2005; 25 (2) 157-164
    CrossrefPubMedGoogle Scholar
  • 39 Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med 2004; 128 (10) 1142-1145
    PubMedGoogle Scholar